Oteseconazole is under clinical development by Mycovia Pharmaceuticals and currently in Phase I for Cryptococcal Meningitis. According to GlobalData, Phase I drugs for Cryptococcal Meningitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Oteseconazole LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oteseconazole overview
Mycovia Pharmaceuticals overview
Mycovia Pharmaceuticals (Mycoyia Pharmaceuticals) formerly known as Viamet Pharmaceuticals Inc, discovers and develops novel medicinal drugs based on metalloenzyme chemistry and biology technology platform. Its product portfolio includes clinical-stage compounds such as VT-1161, an oral inhibitor used for the treatment of onychomycosis and recurrent vulvovaginal candidiasis; VT-1129, an oral agent for the treatment of cryptococcal meningitis; VT-1598, an oral inhibitor to treat invasive fungal infections, including coccidioidomycosis. The company’s proprietary MIDAS technology (Metalloenzyme Inhibitor Design and Synthesis) enables to discover metalloenzyme inhibitors that target fungal CYP51 of both chronic and life threatening fungal infections. Mycoyia Pharmaceuticals is headquartered in Durham, North Carolina, the US.
For a complete picture of Oteseconazole’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.